Urokinase mediates bFgF-induced vascular smooth muscle cell migration under the control of TGFβ

Fibrinolysis and Proteolysis

Volumn 12, Issue 2, 1998, Pages 89-96

  Herbert, J M ^a   Carmeliet, P ^b  

^a SANOFI   (France)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; UROKINASE;

ANIMAL CELL; ARTICLE; BLOOD VESSEL INJURY; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; DRUG EFFECT; DRUG RECEPTOR BINDING; FIBRINOLYSIS; GENE TRANSFER; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; VASCULAR SMOOTH MUSCLE;

EID: 0031777429     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(98)80381-0     Document Type: Article

References (55)

1. Ross R. The pathogenesis of atherosclerosis- an update. N Engl J Med 1986; 314: 488-495.
2. Schwartz S M, Campbell G R, Campbell J H. Replication of smooth muscle cells in vascular disease. Cite Res 1986; 58: 427-437
3. Carmeliet P, Collen D. Targeted gene manipulation and transfer of the plasminogen and coagulation systems in mice. Fibrinolysis 1996; 10: 195-213.
4. Van Leeuwen R T J. Extracellular proteolysis and the migrating vascular smooth muscle cell. Fibrinolysis 1996; 10: 59-74.
5. Herbert J M, Lamarche I, Prabonnaud V, Dol F, Gauthier T, Tissue-type plasminogen activator is a potent mitogen for human aortic smooth muscle cells. J Biol Chem 1994; 269: 3076-3080.
6. More R S, Underwood M J, Brack M J, de Bono D P, Gershlick A H. Changes in vessel wall plasminogen activator activity and smooth muscle cell proliferation and activation after arterial injury. Cardiovasc Res 1995; 29: 22-26.
7. Clowes A W, Clowes M M, Au Y P T, Reidy M A, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990; 67: 61-67.
8. Odekon L E, Sato Y, Rifkin D B. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol 1992; 150: 258-263.
9. Carmeliet P, Moons L, Dewerchin M, et al. Receptor-independent role of urokinase-type plasminogen activator in arterial neointima formation. In press.
10. Korner G, Bjornsson T D, Vlodavsky I. Extracellular matrix produced by cultured corneal and aortic endothelial cells contains active tissue-type and urokinase-type plasminogen activators. J Cell Physiol 1993; 154: 456-465.
11. Clowes A W, Clowes M M, Kirkam T R, Jackson C L, Au Y P T, Kenagy R D. Heparin inhibits the expression of tissue-type plasminogen activator by smooth muscle cells in injured rat carotid artery. Circ Res 1992; 70: 1128-1136.
12. Au T Y P, Kenagy R D, Clowes A W. Heparin selectively inhibits the transcription of tissue-type plasminogen activator in primate arterial smooth muscle cells during mitogenesis. J Biol Chem 1992; 267: 3438-3444.
13. Carmeliet P, Van Vlaenderen I, Ploplis V, Moons L, Plow E, Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. In press.
14. Ross R. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Nature (London) 1993; 362: 801-809.
15. Heimark R L, Twardzik D R, Schwartz S M. Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets. Science 1986; 233: 1078-1080.
16. Muller G, Behrens J, Nussbaumer U, Bohlen P, Birchmeier W. Inhibitory action of transforming growth factor β on endothelial cells. Proc Natl Acad Sci USA 1987; 84: 5600-5604.
17. Saksela O, Moscatelli D, Rifkin D B. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 1987; 105: 957-963.
18. Frater-Schroder M, Muller G, Birchmeier W, Bohlen P. Transforming growth factor-beta inhibits endothelial cell proliferation. Biochem Biophys Res Commun 1986; 137: 295-307.
19. Flaumenhaft R, Abe M, Mignatti P, Rifkin D D, Basic fibroblast growth factor-induced activation of latent transforming growth factor β in endothelial cells: regulation of plasminogen activator activity. J Cell Biol 1992; 118: 901-909.
20. Halloran B G, Prorok G D, So B J, Baxter B T. Transforming growth factor-beta 1 inhibits human arterial smooth-muscle cell proliferation in a growth-rate-dependent manner. Am J Surg 1995; 170: 193-197.
21. Lawrence D A, Pircher R, Jullien P. Conversion of a high molecular weight latent β-TGF from chicken embryo fibroblasts into a low molecular weight active β-TGF under acidic conditions. Biochem Biophys Res Commun 1985; 133: 1026-1034.
22. Pircher R, Jullien P, Lawrence D A. β-transforming growth factor is stored in human blood platelets as a latent high molecular weight complex. Biochem Biophys Res Commun 1986; 136: 30-37
23. Antonelli-Orlidge A A, Saunders K B, Smith S R, D'Amore P. An activated form of transforming growth factor β is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad USA 1989; 86: 4544-4548.
24. Sato Y, Rifkin D B, Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-β1-like molecules by plasmin during co-culture. J Cell Biol 1989; 109: 309-315.
25. Lyons R M, Keski-Oja J, Moses H L. Proteolytic activation of latent transforming growth factor-β from fibroblast-conditioned medium.; Cell Biol 1988; 106: 1659-1665.
26. Lyons R M, Gentry L E, Purchio A F, Moses H L. Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin J Cell Biol 1990; 110: 1361-1367.
27. Sato Y, Tsuboi R, Lyons R M, Moses H L, Rifkin D B. Characterization of the activation of latent TGF-β by Cocultures of endothelial cells and pericytes of smooth muscle cells: a self-regulating system J Cell Biol 1990; 111: 757-763.
28. Odekon L E, Blasi F, Rifkin D B. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGF-β. J Cell Physiol 1994; 158: 398-407.
29. Carmeliet P, Kieckens L, Schoonjans L et al. Plasminogen activator inhibitor-1 gene-deficient mice. J Clin Invest 1993; 92: 2746-2755.
30. Carmeliet P, Schoonjans L, Kieckens L et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-424.
31. Paul R, Herbert J M, Maffrand J P, Lansen J, Modal G, Pereillo J M, Gordon J L. Inhibition of vascular smooth muscle cell proliferation in culture by pentosan polysulphate and related compounds. Thromb Res 1987; 46: 793-801.
32. Sato Y, Rifkin D B. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol 1988; 107: 1199-1205.
33. Todd R F III, Barnathan E S, Bohuslav J, et al. M16 CD 87 cluster workshop report. In: Schlossman XX et al (eds) Leukocyte Typind V: White Cell Differentiation Antigens. Oxford, England: Oxford University Press, 1995.
34. Grobmyer S R, Kuo A, Orishimo M, Okada S, Cines D B, Barnathan E S. Determinants of binding and internalization of tissue-type plasminogen activator by human vascular smooth muscle and endothelial cells. J Biol Chem, 1993; 268: 13291-13300.
35. 2-macroglobulin receptor mediates cellular uptake of pro-urokinase. J Biol Chem 1993; 268: 21862-21867.
36. 2-macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator inhibitor type-1 complex. J Biol Chem 1992; 267: 14543-14546.
37. Okada S S, Grobmyer S R, Barnathan E S. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion. Arterioscler Thromb Vasc Biol 1996; 16: 1269-1276.
38. Ferns G A, Raines E W, Sprugel K H, Motani A S, Reidy M A, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991; 253: 1129-1131.
39. Libby P S, Warner J C, Salomon R N, Birinyl L K. Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma. N Engl J Med 1988; 318: 1493-1496.
40. Majesky M W, Reidy M A, Bowen-Pope D F, Hart C E, Wilcox J N, Schwanz S M. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol 1990; 111: 2149-2156.
41. Lindner V, Lappi D A, Baird A, Majock R A, Reidy M A. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991; 68: 106-112.
42. Weiss R H, Maduri M. The mitogenic effect of thrombin in vascular smooth muscle cells is largely due to basic fibroblast growth factor. J Biol Chem 1993; 268: 5724-5727.
43. Berk B C, Taubman M B, Griendling K K, Cragaoe E J, Fenton J W, Brock T A. Thrombin-stimulated events in cultured vascular smooth-muscle cells. Biochem J 1991; 274: 799-805.
44. Gasic G P, Arenas C P, Gasic T B, Gasic G J. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA 1992; 89: 2317-2320.
45. Herbert J M, Lamarche I, Dol F. Induction of vascular smooth muscle cell growth by selective activation of the thrombin receptor - Effect of heparin. FEBS Lett 1992; 301: 155-158.
46. McNamara C A, Sarembock I J, Gimple L W, Fenton J W, Coughlin S R, Owens G K. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993; 91: 94-98.
47. Carmeliet P, Moons L, Dewerchin M, Stassen J M, Declercq C, Gerard R, Collen D. Receptor-independent role of urokinase-type plasminogen activator in arterial neointima formation. In press.
48. Gualandris A, Presta M. Transcriptional and posttranscriptional regulation of urokinase-type plasminogen activator expression in endothelial cells by basic fibroblast growth factor. J Cell Physiol 1995; 162: 400-409.
49. Watanabe Y, Inaba T, Shimano H, et al. Induction of LDL receptor-related protein during the differentiation of monocyte-macrophages. Possible involvement in the atherosclerotic process. Arterioscler Thromb 1994; 14: 1000-1006.
50. 2-macroglobulin receptor in human normal and atherosclerotic arteries. Arterioscler Thromb 1994; 14: 1438-1444.
51. Noda-Heiny H, Daugherty A, Sobel B E. Augmented urokinase receptor expression in atheroma. Arterioscler Thromb Vasc Biol 1995; 15: 37-43.
52. Baird A, Durkin T. Inhibition of endothelial cell proliferation by type β-transforming growth factor: interactions with acidic and basic fibroblast growth factors. Biochem Biophys Res Commun 1986; 138: 476-482.
53. Moscatelli D. Presta M, Rifkin D B. Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration. Proc Natl Acad Sci USA 1986; 83: 2091-2095.
54. Presta M, Moscatelli D, Joseph-Silverstein J, Rifkin D B. Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. Mol Cell Biol 1986; 6: 4060-4066.
55. Pepper M S, Belin D, Montesano R, Orci L, Vassalli J D, Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 1990; 111: 743-755.